Pharmacological Targets in Chronic Heart Failure with Reduced Ejection Fraction

Heart failure management has been repeatedly reviewed over time. This strategy has resulted in improved quality of life, especially in patients with heart failure with reduced ejection fraction (HFrEF). It is for this reason that new mechanisms involved in the development and progression of heart fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Moloce, Maria-Angela, Costache, Irina-Iuliana, Nicolae, Ana, Onofrei Aursulesei, Viviana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394280/
https://www.ncbi.nlm.nih.gov/pubmed/35892914
http://dx.doi.org/10.3390/life12081112
Descripción
Sumario:Heart failure management has been repeatedly reviewed over time. This strategy has resulted in improved quality of life, especially in patients with heart failure with reduced ejection fraction (HFrEF). It is for this reason that new mechanisms involved in the development and progression of heart failure, along with specific therapies, have been identified. This review focuses on the most recent guidelines of therapeutic interventions, trials that explore novel therapies, and also new molecules that could improve prognosis of different HFrEF phenotypes.

Ejemplares similares